Apolipoprotein E-dependent accumulation of alzheimer disease-related lesions begins in middle age

Annals of Neurology

Volumn 65, Issue 6, 2009, Pages 650-657

  Kok, Eloise ^a,b   Haikonen, Satu ^a,b   Luoto, Teemu ^a,b   Huhtala, Heini ^c   Goebeler, Sirkka ^a,b   Haapasalo, Hannu ^b   Karhunen, Pekka J ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; SILVER;

ADOLESCENT; ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN TISSUE; CHILD; DEATH; DEMENTIA; FEMALE; FINLAND; FRONTAL CORTEX; GENOTYPE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MEMORY DISORDER; MIDDLE AGED; MORTALITY; NEUROFIBRILLARY TANGLE; NEWBORN; ONSET AGE; PREVALENCE; PRIORITY JOURNAL; SENILE PLAQUE; SILVER STAINING; TISSUE MICROARRAY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HETEROZYGOTE DETECTION; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SENILE PLAQUES; YOUNG ADULT;

EID: 67650094927     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21696     Document Type: Article

References (39)

1. O'Brien J, Ames D, Burns A. Dementia. London, UK: Arnold Cop; 2000.
2. Iadecola C. Atherosclerosis and neurodegeneration: unexpected conspirators in alzheimer's dementia. Arterioscler Thromb Vasc Biol 2003;23:1951-1953.
3. Braak E, Braak H, Mandelkow EM. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol 1994;87:554-567.
4. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351-357.
5. Blair CK, Folsom AR, Knopman DS, et al. APOE genotype and cognitive decline in a middle-aged cohort. Neurology 2005;64:268-276.
6. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003;62:1087-1095.
7. The Neuropathological Group of the Medical Research Council Cognitive Function and Ageing Study (CFAS). Pathological correlates of late-onset dementia in a multi-centre, community-based population in England and Wales. Lancet 2001;357:169-175.
8. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507-537.
9. Reiman EM, Chen K, Alexander GE, et al. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci USA 2005;102:8299-8302.
10. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002;137:149-155.
11. van Duijn CM, de Knijff P, Cruts M, et al. Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. Nat Genet 1994;7:74-78.
12. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. JAMA 1997;278:1349-1356.
13. Bretsky P, Guralnik JM, Launer L, et al. The role of APOE-epsilon4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. Neurology 2003;60:1077-1081.
14. Mayeux R, Small SA, Tang M, et al. Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein-E. Neurobiol Aging 2001;22:683-689.
15. Collie A, Maruff P, Shafiq-Antonacci R, et al. Memory decline in healthy older people: implications for identifying mild cognitive impairment. Neurology 2001;56:1533-1538.
16. Corder EH, Saunders AM, Strittmatter WJ, et al. Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology 1995;45:1323-1328.
17. Polvikoski T, Sulkava R, Myllykangas L, et al. Prevalence of Alzheimer's disease in very elderly people: a prospective neuropathological study. Neurology 2001;56:1690-1696.
18. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
19. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
20. Kauppinen T, Martikainen P, Alafuzoff I. Human postmortem brain tissue and 2-mm tissue microarrays. Appl Immunohistochem Mol Morphol 2006;14:353-359.
21. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
22. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 1996;39:62-70.
23. Baum L, Chen L, Ng HK, Pang CP. Apolipoprotein E isoforms in Alzheimer's disease pathology and etiology. Microsc Res Tech 2000;50:278-281.
24. Polvikoski T, Sulkava R, Rastas S, et al. Incidence of dementia in very elderly individuals: a clinical, neuropathological and molecular genetic study. Neuroepidemiology 2006;26:76-82.
25. Yamaguchi H. Polymorphism in senile dementia of the Alzheimer type from a viewpoint of senile plaque formation. Acta Neuropathol 1998;18:98-102.
26. Ghebremedhin E, Schultz C, Braak E, Braak H. High frequency of apolipoprotein E e4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes. Exp Neurol 1998;153:152-155.
27. Thomas P, Fenech M. A review of genome mutation and Alzheimer's disease. Mutagenesis 2007;22:15-33.
28. Behl C. Eostrogen as a neuroprotective hormone. Nat Rev Neurosci 2002;3:433-442.
29. Qiu C, Kivipelto M, Aguero-Torres H, et al. Risk and protective effects of the APOE gene towards Alzheimer's disease in the Kungsholmen project: variation by age and sex. J Neurol Neurosurg Psychiatry 2004;75:828-833.
30. Kivipelto M, Helkala EL, Nissinen A, et al. Vascular risk factors, ApoE ε4 allele, and gender and the risk of Alzheimer's disease: perspectives on prevention. Drug Dev Res 2002;56:85-94.
31. Lehtinen S, Lehtimaki T, Sisto T, et al. Apolipoprotein E, serum lipids, myocardial infarction and severity of angiographically verified coronary artery disease in men and women. Atherosclerosis 1995;114:83-91.
32. Sparks DL, Scheff SW, Liu H, et al. Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in nondemented individuals with the apolipoprotein E4 allele: comparison to confirmed Alzheimer's disease patients. J Neurol Sci 1996;138:97-104.
33. Ghebremedhin E, Schultz C, Thal DR, et al. Gender and age modify the association between APOE and AD-related neuropathology. Neurology 2001;56:1696-1701.
34. Berg L, McKeel DW, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326-335.
35. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7:180-184.
36. Tiraboschi P, Hansen LA, Masliah E, et al. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 2004;62:1977-1983.
37. Alafuzoff I, Pikkarainen M, Al-Sarraj S, et al. Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol 2006;65:740-757.
38. Kivipelto M, Ngandu T, Fratiglioni L, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005;62:1556-1560.
39. Kalaria RN. Vascular factors in Alzheimer's disease. Int Psychogeriatr 2003;15:47-52.